UNSPSC 51151666: Tolterodine

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WHE7A56U7K. European Medicines Agency schedules Tolterodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11180MIG. Tolterodine generally arises in the molecular formula C22H31NO.

UNSPSC 51151666 Tolterodine is a Commodity code representing pharmaceutical procurement activity, though the recent state and local opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida issued an IFB for naloxone and safe drug deactivation systems (IFB60459723LAS, due July 26, 2023), while the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs (HHS0017013, due April 3, 2026) — neither directly aligned with tolterodine-specific purchasing. The code appears to see activity from county health departments and state HHS agencies pursuing pharmaceutical procurement through competitive bidding and market-intelligence mechanisms, though the mismatch between the nominal code and the actual solicitations suggests either miscoding at the source or limited recent tolterodine-specific state and local demand.

Recent activity concentrates in Florida and Texas. The Seminole County naloxone procurement called for 1,900 units and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with one-year renewal option; the Texas RFI sought vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels, targeting self-insured employer and government health plans. Neither opportunity explicitly names tolterodine as a line item, and no other state and local solicitations under this code appear in the recent record. Vendors pursuing pharmaceutical supply contracts in this space should monitor county health procurement for acute-care and community health initiatives and state HHS agencies for pharmacy benefit program modernization, but the current code activity is sparse and may reflect data-quality issues rather than robust state and local demand for tolterodine specifically.